Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa.

Ruff P, Cubasch H, Joffe M, Rosenbaum E, Murugan N, Tsai MC, Ayeni O, Crew KD, Jacobson JS, Neugut AI.

Cancer Manag Res. 2018 Feb 9;10:279-286. doi: 10.2147/CMAR.S148317. eCollection 2018.

PMID:
29467582
2.

A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions or Benign Breast Disease.

Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ.

Cancer Prev Res (Phila). 2018 Feb 16. pii: canprevres.0354.2017. doi: 10.1158/1940-6207.CAPR-17-0354. [Epub ahead of print]

PMID:
29453232
3.

Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Gunther JE, Lim EA, Kim HK, Flexman M, Altoé M, Campbell JA, Hibshoosh H, Crew KD, Kalinsky K, Hershman DL, Hielscher AH.

Radiology. 2018 Feb 12:161041. doi: 10.1148/radiol.2018161041. [Epub ahead of print]

PMID:
29431574
4.

Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women.

McGuinness JE, Ueng W, Trivedi MS, Yi HS, David R, Vanegas A, Vargas J, Sandoval R, Kukafka R, Crew KD.

Cancer Epidemiol Biomarkers Prev. 2018 Jan 30. pii: cebp.0009.2017. doi: 10.1158/1055-9965.EPI-17-0009. [Epub ahead of print]

PMID:
29382701
5.

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).

Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS.

J Natl Cancer Inst. 2018 Jan 18. doi: 10.1093/jnci/djx259. [Epub ahead of print]

PMID:
29361042
6.

What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women?

Crew KD.

Cancer Prev Res (Phila). 2017 Nov;10(11):609-611. doi: 10.1158/1940-6207.CAPR-17-0281. Epub 2017 Oct 4.

PMID:
28978567
7.

Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting.

Finkelstein J, Wood J, Crew KD, Kukafka R.

AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:58-67. eCollection 2017.

8.

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.

Potkul RK, Unger JM, Livingston RB, Crew KD, Wilczynski SP, Salomon CG, Smith BL, Wong L, Campbell DL, Einspahr DE, Anderson GL, Hershman D, Goodman GE, Brown PH, Meyskens FL, Albain KS.

NPJ Breast Cancer. 2016 Aug 10;2:16024. doi: 10.1038/npjbcancer.2016.24. eCollection 2016.

9.

South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment.

Cubasch H, Ruff P, Joffe M, Norris S, Chirwa T, Nietz S, Sharma V, Duarte R, Buccimazza I, Čačala S, Stopforth LW, Tsai WY, Stavsky E, Crew KD, Jacobson JS, Neugut AI.

J Glob Oncol. 2017 Apr;3(2):114-124. doi: 10.1200/JGO.2015.002675.

10.

How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?

Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS.

NPJ Breast Cancer. 2017 May 19;3:20. doi: 10.1038/s41523-017-0021-y. eCollection 2017.

11.

Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.

Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD.

Cancer Prev Res (Phila). 2017 Aug;10(8):434-441. doi: 10.1158/1940-6207.CAPR-17-0100. Epub 2017 Jun 13.

PMID:
28611039
12.

The Impact of Mental Illness on Uptake of Genetic Counseling for Hereditary Breast Cancer and Ovarian Cancer in a Multiethnic Cohort of Breast Cancer Patients.

Ackerman MG, Shapiro PA, Coe A, Trivedi MS, Crew KD.

Breast J. 2017 Sep;23(5):519-524. doi: 10.1111/tbj.12791. Epub 2017 Mar 21.

PMID:
28323373
13.

Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women.

Coe AM, Ueng W, Vargas JM, David R, Vanegas A, Infante K, Trivedi M, Yi H, Dimond J, Crew KD, Kukafka R.

AMIA Annu Symp Proc. 2017 Feb 10;2016:411-420. eCollection 2016.

14.

Population-Based Study of Attitudes toward BRCA Genetic Testing among Orthodox Jewish Women.

Tang EY, Trivedi MS, Kukafka R, Chung WK, David R, Respler L, Leifer S, Schechter I, Crew KD.

Breast J. 2017 May;23(3):333-337. doi: 10.1111/tbj.12736. Epub 2016 Nov 30.

PMID:
27900810
15.

Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors.

Greenlee H, Molmenti CL, Crew KD, Awad D, Kalinsky K, Brafman L, Fuentes D, Shi Z, Tsai WY, Neugut AI, Hershman DL.

J Cancer Surviv. 2016 Dec;10(6):956-963. Epub 2016 Apr 21.

PMID:
27100859
16.

Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled Trial.

Greenlee H, Ogden Gaffney A, Aycinena AC, Koch P, Contento I, Karmally W, Richardson JM, Shi Z, Lim E, Tsai WY, Santella RM, Blaner WS, Clugston RD, Cremers S, Pollak S, Sirosh I, Crew KD, Maurer M, Kalinsky K, Hershman DL.

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1491-1502. Epub 2016 Jul 26.

17.

Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.

Kalinsky K, Zheng T, Hibshoosh H, Du X, Mundi P, Yang J, Refice S, Feldman SM, Taback B, Connolly E, Crew KD, Maurer MA, Hershman DL.

Clin Transl Oncol. 2017 Feb;19(2):180-188. doi: 10.1007/s12094-016-1521-1. Epub 2016 Jun 15.

PMID:
27305912
18.

Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.

Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL.

Breast Cancer Res Treat. 2016 Apr;156(3):453-464. doi: 10.1007/s10549-016-3759-2. Epub 2016 Mar 25.

19.

Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors.

Aycinena AC, Valdovinos C, Crew KD, Tsai WY, Mata JM, Sandoval R, Hershman D, Greenlee H.

J Immigr Minor Health. 2017 Feb;19(1):120-129. doi: 10.1007/s10903-015-0310-1.

PMID:
26801931
20.

Interaction between polyunsaturated fatty acids and genetic variants in relation to breast cancer incidence.

Khankari NK, Bradshaw PT, Steck SE, He K, Olshan AF, Ahn J, Terry MB, Crew KD, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD.

J Cancer Epidemiol Prev (iMedPub). 2016;1(1). pii: 2. Epub 2016 Dec 30.

21.

Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.

Chen EI, Crew KD, Trivedi M, Awad D, Maurer M, Kalinsky K, Koller A, Patel P, Kim Kim J, Hershman DL.

PLoS One. 2015 Dec 28;10(12):e0145816. doi: 10.1371/journal.pone.0145816. eCollection 2015.

22.

Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients.

Greenlee H, Crew KD, Capodice J, Awad D, Jeffres A, Unger JM, Lew DL, Hansen LK, Meyskens FL Jr, Wade JL 3rd, Hershman DL.

J Acupunct Meridian Stud. 2015 Jun;8(3):152-8. doi: 10.1016/j.jams.2015.03.006. Epub 2015 Apr 23.

23.

Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Crew KD.

Am Soc Clin Oncol Educ Book. 2015:e50-8. doi: 10.14694/EdBook_AM.2015.35.e50.

24.

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, Greenlee H, Lew DL, Minasian LM, Till C, Wade JL 3rd, Meyskens FL, Moinpour CM.

J Clin Oncol. 2015 Jun 10;33(17):1910-7. doi: 10.1200/JCO.2014.59.5595. Epub 2015 May 4.

25.

Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.

Reimers LL, Sivasubramanian PS, Hershman D, Terry MB, Greenlee H, Campbell J, Kalinsky K, Maurer M, Jayasena R, Sandoval R, Alvarez M, Crew KD.

Breast J. 2015 Jul-Aug;21(4):377-86. doi: 10.1111/tbj.12418. Epub 2015 Apr 16.

26.

Dietary modifications, weight loss, and changes in metabolic markers affect global DNA methylation in Hispanic, African American, and Afro-Caribbean breast cancer survivors.

Delgado-Cruzata L, Zhang W, McDonald JA, Tsai WY, Valdovinos C, Falci L, Wang Q, Crew KD, Santella RM, Hershman DL, Greenlee H.

J Nutr. 2015 Apr;145(4):783-90. doi: 10.3945/jn.114.202853. Epub 2015 Feb 4.

27.

Atypical hyperplasia of the breast.

Reimers LL, Crew KD, Terry MB.

N Engl J Med. 2015 Mar 26;372(13):1270-1. doi: 10.1056/NEJMc1501046#SA2. No abstract available.

PMID:
25806931
28.

Genetic polymorphisms in DNA repair and oxidative stress pathways may modify the association between body size and postmenopausal breast cancer.

McCullough LE, Eng SM, Bradshaw PT, Cleveland RJ, Steck SE, Terry MB, Shen J, Crew KD, Rossner P Jr, Ahn J, Ambrosone CB, Teitelbaum SL, Neugut AI, Santella RM, Gammon MD.

Ann Epidemiol. 2015 Apr;25(4):263-9. doi: 10.1016/j.annepidem.2015.01.009. Epub 2015 Jan 24.

29.

Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer.

Crew KD, Xiao T, Thomas PS, Terry MB, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice SR, Hershman DL.

Int J Food Sci Nutr Diet. 2015;2015(Suppl 1):1-16. doi: 10.19070/2326-3350-SI01001. Epub 2015 Feb 23.

30.

Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools.

Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, Dimond J, Finkelstein J, Infante K, Trivedi M, David R, Vargas J, Crew KD, Kukafka R.

AMIA Annu Symp Proc. 2015 Nov 5;2015:1352-60. eCollection 2015.

31.

Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk.

Reimers LL, Crew KD, Bradshaw PT, Santella RM, Steck SE, Sirosh I, Terry MB, Hershman DL, Shane E, Cremers S, Dworakowski E, Teitelbaum SL, Neugut AI, Gammon MD.

Cancer Causes Control. 2015 Feb;26(2):187-203. doi: 10.1007/s10552-014-0497-9. Epub 2014 Nov 25.

32.

Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.

Kalinsky K, Lim EA, Andreopoulou E, Desai AM, Jin Z, Tu Y, Hibshoosh H, Wang A, Greenlee H, Crew KD, Maurer M, Sparano JA, Hershman DL.

Cancer Invest. 2014 Nov;32(9):439-44. doi: 10.3109/07357907.2014.958232. Epub 2014 Sep 25.

33.

Mammographic density and serum 25-hydroxyvitamin D levels.

Crew KD, Campbell J, Reynolds D, Fulton L, Flom JD, Liao Y, Tehranifar P, Terry MB.

Nutr Metab (Lond). 2014 Apr 17;11:18. doi: 10.1186/1743-7075-11-18. eCollection 2014.

34.

Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer.

Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL.

J Hum Nutr Diet. 2015 Jun;28(3):272-82. doi: 10.1111/jhn.12229. Epub 2014 Mar 19.

35.

Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.

Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, Taback B, Ahmad A, Cremers S, Hibshoosh H, Maurer M, Hershman DL.

Cancer Invest. 2014 May;32(4):150-7. doi: 10.3109/07357907.2014.889706. Epub 2014 Mar 7.

36.

Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer.

Work ME, Reimers LL, Quante AS, Crew KD, Whiffen A, Terry MB.

Int J Cancer. 2014 Oct 1;135(7):1740-4. doi: 10.1002/ijc.28825. Epub 2014 Mar 17.

37.

Genetic variation in multiple biologic pathways, flavonoid intake, and breast cancer.

Khankari NK, Bradshaw PT, McCullough LE, Teitelbaum SL, Steck SE, Fink BN, Xu X, Ahn J, Ambrosone CB, Crew KD, Terry MB, Neugut AI, Chen J, Santella RM, Gammon MD.

Cancer Causes Control. 2014 Feb;25(2):215-26. doi: 10.1007/s10552-013-0324-8. Epub 2013 Nov 27.

38.

Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Reimers L, Crew KD.

Curr Breast Cancer Rep. 2012 Sep 1;4(3):207-215.

39.

Polymorphisms in DNA repair genes, recreational physical activity and breast cancer risk.

McCullough LE, Santella RM, Cleveland RJ, Millikan RC, Olshan AF, North KE, Bradshaw PT, Eng SM, Terry MB, Shen J, Crew KD, Rossner P Jr, Teitelbaum SL, Neugut AI, Gammon MD.

Int J Cancer. 2014 Feb 1;134(3):654-63. doi: 10.1002/ijc.28383. Epub 2013 Aug 29.

40.

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS.

J Clin Oncol. 2013 Jul 10;31(20):2627-33. doi: 10.1200/JCO.2012.44.8738. Epub 2013 Jun 3.

41.

Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors.

Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brafman L, Jayasena R, Tsai WY, Neugut AI, Crew KD.

Breast Cancer Res Treat. 2013 Apr;138(3):795-806. doi: 10.1007/s10549-013-2486-1. Epub 2013 Mar 31.

PMID:
23542954
42.

Vitamin d: are we ready to supplement for breast cancer prevention and treatment?

Crew KD.

ISRN Oncol. 2013;2013:483687. doi: 10.1155/2013/483687. Epub 2013 Feb 26.

43.

A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors.

Greenlee HA, Crew KD, Mata JM, McKinley PS, Rundle AG, Zhang W, Liao Y, Tsai WY, Hershman DL.

Obesity (Silver Spring). 2013 Jan;21(1):65-76. doi: 10.1002/oby.20245.

44.

Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.

Clarke Hillyer G, Neugut AI, Crew KD, Kalinsky K, Maurer MA, Rotsides DZ, Danaceau J, Hershman DL.

J Oncol Pract. 2012 Sep;8(5):e100-4. doi: 10.1200/JOP.2011.000487. Epub 2012 Jun 26.

45.

Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.

Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL.

Support Care Cancer. 2013 Apr;21(4):1077-87. doi: 10.1007/s00520-012-1628-z. Epub 2012 Nov 1.

46.

Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.

Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL.

Cancer Prev Res (Phila). 2012 Sep;5(9):1144-54. doi: 10.1158/1940-6207.CAPR-12-0117. Epub 2012 Jul 24.

47.

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.

Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD.

Breast Cancer Res Treat. 2011 Feb;125(3):767-74. doi: 10.1007/s10549-010-1278-0. Epub 2010 Dec 3.

PMID:
21128110
48.

Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.

Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL.

J Clin Oncol. 2010 Mar 1;28(7):1154-60. doi: 10.1200/JCO.2009.23.4708. Epub 2010 Jan 25.

PMID:
20100963
49.

Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.

Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E.

J Clin Endocrinol Metab. 2010 Feb;95(2):559-66. doi: 10.1210/jc.2009-1366. Epub 2009 Dec 18.

50.

Ethnicity and persistent symptom burden in breast cancer survivors.

Fu OS, Crew KD, Jacobson JS, Greenlee H, Yu G, Campbell J, Ortiz Y, Hershman DL.

J Cancer Surviv. 2009 Dec;3(4):241-50. doi: 10.1007/s11764-009-0100-7. Epub 2009 Oct 27.

Supplemental Content

Support Center